Table 4.
Goal | Exploratory studies: mechanism/target-focused | Therapeutic studies: compound-focused |
---|---|---|
Study design | Efficacy data should be assessed through multiple outcome measures. | Efficacy results should be demonstrated in more than one model. |
Both exploratory and therapeutic studies should be randomized, placebo-controlled, and blinded, with a dose response. | ||
In vivo model considerations for both types of studies include pathogenic stage, age, length of treatment required, and exclusion criteria. | ||
ADME | Studies should include initial physicochemical property considerations and terminal blood and brain tissue sampling for assurance of target exposure and possible pharmacokinetics verification. | Studies should include ADME profiling, full pharmacokinetics/pharmacodynamics analysis and distribution/exposure of parent compound and metabolites. |
Toxicity | Defined toxicity assessment is not needed, but a simple drug tolerability assay should be included. | Toxicology should be assessed in the model being studied, with treatment conducted at levels reliably below adverse event doses. |
Statistics plan | While statistical considerations need not be as stringent, prospective power analysis should take into account variability in the model itself and in outcome measure readouts. | Prospective study design should include sample size power analyses, statistical evaluation plan, primary and secondary outcome measures, blinding, and randomization. |
ADME, absorption, distribution, metabolism, and excretion.